BSEConcord Drugs LtdMinimalNeutral
Announced Fri, 10 Apr · 18:13 IST

Certificate under Reg 74(5)

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+8.5%1-day move
₹74.18
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+8.5+11.9+15.9+13.9+18.0+15.7+11.9+9.2+10.4-3.1
Up moveDown movePending
AI summary

Concord Drugs Limited has submitted a compliance certificate from its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, for the quarter ended 31st March 2026. The certificate confirms that the R&T Agent properly handled dematerialization requests received between 1st January 2026 and 31st March 2026. Specifically, the agent confirmed compliance with three key procedures: processing dematerialized securities that are listed on the stock exchange, mutilating and cancelling physical share certificates received from participants, and updating records to show the depository as the registered owner. This is a routine regulatory filing required under SEBI regulations.

Likely market impact

This is a standard compliance filing with no direct impact on stock price or shareholder value. It simply confirms proper handling of dematerialization procedures during the quarter.